Expressing concern over higher generic drug prices, the chair of the House Committee on Oversight and Government Reform and a dozen other Republican committee members recently wrote to the acting Food and Drug Administration (FDA) commissioner requesting information about the agency’s process for reviewing generic drug applications.
Nearly 86% of all prescriptions filled in the United States are for generic drugs, and their average cost is typically 80% to 85% lower than brand equivalents, oversight committee chair Jason Chaffetz (R, Utah) and colleagues wrote Acting FDA Commissioner Stephen Ostroff, MD (http://1.usa.gov/1TH9yu6).
Rita Rubin. Congress Seeks FDA Documents About Generic Drug Approvals. JAMA. 2016;315(6):549. doi:10.1001/jama.2016.0003